MediciNova enters deal to take part in long Covid treatment trial
The trial of MN-166 will commence following regulatory review and finalisation of the protocol.

The trial of MN-166 will commence following regulatory review and finalisation of the protocol.
IMC-2 merges valacyclovir and celecoxib together to hinder the herpes virus from activating and replicating.
AIM ImmunoTech leadership offers new details on a potential Phase II trial of Ampligen in long Covid patients with chronic…
ByIn an exclusive, Ashvattha Therapeutics CEO Jeff Cleland discusses a potential trial of OP-101 in long Covid patients experiencing chronic…
ByIn the trial, up to 400mg daily dose of FB2001 was found to be safe and well tolerated.
The trial will enrol 3,600 participants in Mexico, US, Argentina, Spain, UK, Colombia, South Africa, Philippines and Brazil.
The trial will analyse the safety, tolerability, pharmacokinetics and initial efficacy of ASC10 tablets in Covid-19 patients.
The institute will partner with RTI International to expedite the trial process and launch multi-intervention studies.
Thank you for subscribing to Clinical Trials Arena